- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Emergency Filtration Products, Inc. (EFP) (OTCBB: EMFP) today announced that it has entered into an agreement to privately place up to $1,650,000 of its common stock with two individual investors. The financing is comprised of three tranches; the first tranche has already been completed, netting the company $750,000. EFP expects the other two tranches, which will net the company an additional $900,000, to be completed on the first of March and May 2007, respectively. The company intends to use the proceeds from this financing to complete the process of obtaining FDA approval for its NanoMask products.
About Emergency Filtration Products
EFP is an air filtration products manufacturer whose patented 2H Technology(TM) ( http://emergencyfiltration.com/Technology/2HTechnology.htm ) filter system has produced filtration efficiencies of "greater than 99.99%" at a particulate size of 0.027 microns. EFP's initial products were developed for the medical market: the Vapor Isolation Valve(TM) ( http://emergencyfiltration.com/Products/VIV.htm ) and RespAide® ( http://emergencyfiltration.com/Products/RespAide.htm ) CPR Isolation Mask used for resuscitation of respiratory/cardiac arrest cases; and 2H Breathing Circuit Filter for ventilators, respirators and anesthesia circuitry. Each has received FDA approval. The Company also markets an Automated External Defibrillator Prep Kit featuring RespAide; and the NanoMask®, ( http://emergencyfiltration.com/Products/NanoMask.htm ) a nanotechnology enhanced environmental mask. In addition to filtration products, the company supplies Superstat®, ( http://emergencyfiltration.com/Products/Superstat.htm ) a modified hemostatic collagen, to the U.S. Military for surgery and extreme wound care.
About the NanoMask®
EFP's nanoparticle-enhanced environmental mask, the NanoMask® relies on the company's core 2H Technology(TM) filtration system, which utilizes a combination of hydrophobic and hydrophilic filters able to capture, isolate and or eradicate bacterial and viral microorganisms with efficiencies of 99.999%.
Safe Harbor Statement
This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. EFP does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future results of the company could differ significantly from such forward-looking statements. Specifically, approval from the FDA, if attained, may not translate into significant sales of EFP's products. Sales may be dependent on the success of future marketing campaigns, and both the perceived need for EFP's products and the competitive performance of such products in the marketplace.
For more information, please click here
PAN Consultants Ltd.
Philippe Niemetz, 800-477-7570 or 212-344-6464
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanotech Grants Options September 22nd, 2016
Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Unusual quantum liquid on crystal surface could inspire future electronics October 22nd, 2016
Nanosciences: Genes on the rack October 21st, 2016
Nanoparticle vaccinates mice against dengue fever October 21st, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016